KALV

KalVista Pharmaceuticals Presents Phase 2 Clinical Data of Oral KVD900 for Treatment of HAE at C1-Inhibitor Deficiency & Angioedema Workshop

KalVista Pharmaceuticals Expands Senior Leadership Team with Appointment of Paul K. Audhya, MD, MBA as Chief Medical Officer

KalVista Stock Falls After FDA Institutes Clinical Hold On Hereditary Angioedema Trial With KVD824

KalVista Pharmaceuticals Provides Regulatory Update for Phase 2 Clinical Trial of KVD824

KalVista Pharmaceuticals, Inc. (KALV) Reports Q3 Loss, Misses Revenue Estimates

KalVista Pharmaceuticals Reports Third Fiscal Quarter Results

KalVista Pharmaceuticals, Inc. (KALV) Expected to Beat Earnings Estimates: Should You Buy?